Tel Aviv University Future Technology Development L.P.
|Tel Aviv University Future Technology Development L.P. Patent applications|
|Patent application number||Title||Published|
|20130095032||LIPIDATED GLYCOSAMINOGLYCAN PARTICLES AND THEIR USE IN DRUG AND GENE DELIVERY FOR DIAGNOSIS AND THERAPY - Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.||04-18-2013|
|20130078233||COMPOSITIONS AND METHODS USING SAME FOR TREATING AMYLOID-ASSOCIATED DISEASES - Compounds having one or more phenol moieties, derivatives thereof, compositions containing same and uses thereof for the treatment of amyloid-associated diseases are provided.||03-28-2013|
|20120171261||FORMULATIONS OF WATER INSOLUBLE OR POORLY WATER SOLUBLE DRUGS IN LIPIDATED GLYCOSAMINOGLYCAN PARTICLES AND THEIR USE FOR DIAGNOSTICS AND THERAPY - The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.||07-05-2012|
|20120150050||APPARATUS AND METHOD FOR ESTIMATING STROKE VOLUME OF THE HEART USING BIO-IMPEDANCE TECHNIQUES - A method of estimating stroke volume of the heart is described. In this method, the volume of the heart is estimated from electrical impedance data of the chest, at two different phases of the cardiac cycle. The stroke volume is estimated from the difference between the volumes estimated at the two phases.||06-14-2012|
|20100240726||COMPOSITIONS FOR TREATING AMYLOID ASSOCIATED DISEASES - Indole derivatives, compositions including same, and methods utilizing same for the treatment of amyloid associated diseases, such as type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis, and prion-related encephalopathies are provided.||09-23-2010|
|20100105608||Peptides and methods using same for diagnosis and treatment of amyloid-associated disease - Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.||04-29-2010|
|20100022459||Peptides directed for diagnosis and treatment of amyloid-associated diseases - Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X—Y or Y—X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.||01-28-2010|
|20090209041||Peptides and methods for inhibiting amyloid formation - A peptide comprising at least 5 amino acid residues and less than 15 amino acid residues, the peptide including an amino acid sequence as set forth in SEQ ID NO: 7 as well as pharmaceutical compositions, kits and methods for diagnosing and treating amyloid associated diseases.||08-20-2009|
|20090142656||3-D MICROBATTERIES BASED ON INTERLACED MICRO-CONTAINER STRUCTURES - An electrical energy storage device (||06-04-2009|
|20090062180||Glycogen synthase kinase-3 inhibitors - Novel conjugates that are capable of inhibiting GSK-3 activity, a process of producing same, pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions are disclosed. Methods of treating affective disorders using GSK-3 inhibitors are further disclosed.||03-05-2009|
|20080312188||Glycogen synthase kinase-3 inhibitors - Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.||12-18-2008|
Patent applications by Tel Aviv University Future Technology Development L.P.